Corrigendum to "Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies"
Saved in:
Format: | Book |
---|---|
Published: |
SAGE Publishing,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
by: Brian Baker, et al.
Published: (2022) -
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
by: Damiana Scuteri, et al.
Published: (2021) -
Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
by: Altamura C, et al.
Published: (2023) -
Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
by: Brian Baker, et al.
Published: (2020) -
Pharmacokinetics of Tildipirosin in Plasma, Milk, and Somatic Cells Following Intravenous, Intramuscular, and Subcutaneous Administration in Dairy Goats
by: Juan Sebastián Galecio, et al.
Published: (2022)